Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2014

View Archived Issues

The discovery of a new protein target and novel compounds for the treatment of malaria

Receptos initiates phase III portion of RADIANCE trial of RPC-1063 for relapsing MS

Capricor and Janssen enter collaboration to develop cell therapies for cardiovascular applications

Cytomedix completes enrollment in RECOVER-Stroke trial of ALD-401 in cerebral ischemic stroke

Cellceutix files application to commence trials of anti-psoriasis drug Prurisol

RedHill Biopharma reports pharmacokinetic results for RHB-104

GS-9973 demonstrates promising activity in phase II trial

Vaccination with ImMucin leads to promising clinical response in phase I/II trials

High-throughput screening based on physiological function for novel indications of existing drugs

Horizon Discovery forms oncology agreement with AstraZeneca

Cenicriviroc, a dual CCR2/CCR5 inhibitor, as novel therapeutic strategy for liver fibrosis

Catalyst Pharmaceutical completes type B meeting with FDA for Firdapse

Generex Biotechnology confirms database lock for AE-37 breast cancer vaccine trial

ST-10 meets endpoints in phase III AEGIS trial for iron deficiency anemia in IBD

Cytovir ADV ready to receive orphan drug designation in Europe

e-Therapeutics provides update on phase I ETS-2101 trial

Ossianix forms research collaboration with Lundbeck

Committee recommends stopping Imbruvica study based on significant survival improvement

Abraxane plus gemcitabine receives European approval for metastatic pancreatic cancer

Orexigen Therapeutics receives new FDA action date for Contrave

Sutro Biopharma and Memorial Sloan-Kettering to produce antibodies for neuroblastoma

Qiagen launches therascreen IDH1/2 test for gliomas and collaborates with Mayo Clinic

Allergan and Medytox close licensing agreement covering neurotoxin product candidates

FDA grants orphan drug status to Alitair's Erdosteine in bronchiectasis

Japanese investigators patent novel OX1/OX2 receptor antagonists

Scil Proteins discloses new fusion proteins for cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...